[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Flanagan KH, Brennan DC: EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int; 2006 Apr;19(4):338-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated recurrent Hodgkin's disease after renal transplantation.
  • Hodgkin's disease is recognized as part of the spectrum of post-transplantation lymphoproliferative disorders (PTLD), although it is still an uncommon de novo malignancy in this population.
  • Epstein-Barr virus (EBV) has been linked to both post-transplant non-Hodgkin's lymphomas and Hodgkin's disease.
  • We report a case of recurrent Hodgkin's disease in a patient who received a renal transplant in childhood and later developed EBV-associated Hodgkin's disease with remission after chemotherapy until subsequent relapse 9 years later that was successfully treated.
  • To our knowledge, this is the first report of recurrent Hodgkin's disease in a transplant recipient.
  • We briefly discuss the pathogenesis of and risk factors for EBV-related PTLD, utility of EBV load surveillance, and the options for treatment of PTLD including immunosuppression reduction, antiviral therapy, anti-CD20 monoclonal antibodies, cytotoxic T cells, and the possible roles of interferon-alpha and rapamycin.
  • [MeSH-major] Epstein-Barr Virus Infections / etiology. Hodgkin Disease / etiology. Kidney Transplantation / adverse effects
  • [MeSH-minor] Adult. Herpesvirus 4, Human / isolation & purification. Humans. Kidney Failure, Chronic / surgery. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / therapy. Male. Recurrence. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1990 Jul;137(1):13-8 [2164775.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):1016-23 [15472855.001]
  • [Cites] Pediatr Transplant. 2004 Feb;8(1):87-90 [15009846.001]
  • [Cites] Am J Transplant. 2001 Jul;1(2):103-8 [12099356.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1723-8 [2100991.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]
  • [Cites] Transplantation. 1997 Sep 27;64(6):848-52 [9326409.001]
  • [Cites] Curr Biol. 1998 Mar 12;8(6):R196-8 [9512412.001]
  • [Cites] J Heart Lung Transplant. 1998 Dec;17(12):1161-6 [9883755.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] Transpl Int. 2005 Jun;18(6):643-50 [15910287.001]
  • [Cites] Transpl Int. 2004 Feb;17(2):89-96 [14652716.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2592-8 [11895798.001]
  • (PMID = 16573551.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC1448701
  •  go-up   go-down


2. Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M: MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Clin Cancer Res; 2006 Jan 15;12(2):529-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
  • PURPOSE: MOPPEBVCAD (mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine) chemotherapy with limited radiotherapy was devised in 1987 to reduce late toxicity and second tumor incidence while trying to improve effectiveness through increases of dose intensity and dose density.
  • EXPERIMENTAL DESIGN: The drugs of three previous alternating regimens [CAD (lomustine, melphalan, and vindesine), MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), and ABV (doxorubicin, bleomycin, and vinblastine)] were intensified and hybridized, the cumulative dose of mechlorethamine was lowered, and irradiation was delivered to no more than two sites either bulky or partially responding to chemotherapy.
  • RESULTS: A total of 307 previously untreated advanced-stage patients underwent MOPPEBVCAD chemotherapy.
  • The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6.
  • Given its response/late toxicity balance, MOPPEBVCAD does not undermine the leading role of ABVD as first-line regimen but can be indicated as a very effective second-line conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / toxicity. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug-Related Side Effects and Adverse Reactions. Epirubicin / administration & dosage. Epirubicin / toxicity. Female. Humans. Lomustine / administration & dosage. Lomustine / toxicity. Male. Mechlorethamine / administration & dosage. Mechlorethamine / toxicity. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / toxicity. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / toxicity. Vincristine / administration & dosage. Vincristine / toxicity. Vindesine / administration & dosage. Vindesine / toxicity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428496.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; 80168379AG / Doxorubicin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CAD protocol 2; EBV protocol; MOPP protocol
  •  go-up   go-down


3. Kast RE: Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir. Yonsei Med J; 2006 Apr 30;47(2):287-90
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir.
  • This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46:425-30) on a full and sustained remission of Hodgkin's lymphoma (HL) after a single day of chemotherapy.
  • A septic episode required stopping chemotherapy and starting amphotericin B and acyclovir.
  • A review of research supporting the notion that amphotericin B can reactivate latent Epstein-Barr virus and thus allow acyclovir to kill infected HL cells is given.
  • If successful, amphotericin B and acyclovir treatment could be extended to other EBV-driven cancers such as Burkitt's lymphoma, nasopharyngeal carcinoma and the occasional EBV-related epithelial cancer of the breast, colon, prostate, and others.
  • [MeSH-major] Acyclovir / therapeutic use. Amphotericin B / pharmacology. Drug Synergism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / drug therapy. Hodgkin Disease / virology
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Burkitt Lymphoma / virology. Ganciclovir / therapeutic use. Humans. Remission Induction. Tumor Necrosis Factor-alpha / metabolism. Virus Activation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Yonsei Med J. 2005 Jun 30;46(3):425-30 [15988816.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Blut. 1990 Dec;61(6):346-9 [2291981.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37561-8 [12860979.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Antimicrob Agents Chemother. 1984 Jun;25(6):772-4 [6331301.001]
  • [Cites] J Virol. 2005 May;79(9):5875-9 [15827204.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Apr;49(4):1617-21 [15793154.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):384-8 [9458076.001]
  • [Cites] N Engl J Med. 1996 Sep 5;335(10):721-9 [8786764.001]
  • [Cites] Pharmacol Ther. 1994;64(3):529-64 [7724661.001]
  • (PMID = 16642564.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Tumor Necrosis Factor-alpha; 7XU7A7DROE / Amphotericin B; P9G3CKZ4P5 / Ganciclovir; X4HES1O11F / Acyclovir
  • [Other-IDs] NLM/ PMC2687644
  •  go-up   go-down


Advertisement
4. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol; 2007 Dec;82(12):1106-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
  • Rheumatoid arthritis (RA) is associated with an increased risk of developing lymphoma.
  • Although the pathogenesis is still unclear, the increased risk appears to be related to the high inflammatory activity of RA, immunosuppressive agents, or Epstein-Barr virus (EBV) infection.
  • We investigated the relationship between EBV latent infection and methotrexate (MTX)-associated lymphoma in RA patients.
  • Nine patients were diagnosed with non-Hodgkin's lymphoma (NHL) during MTX treatment for RA in a multicenter study.
  • The pathologic findings were consistent with diffuse large B-cell lymphoma in 8 patients and peripheral T-cell lymphoma, unspecified in 1.
  • EBV infection was detected in 3 patients by in situ hybridization.
  • Both patients who had a CR and 1 who had SD were positive for EBV.
  • Further examination of the latent EBV infection patterns revealed that 2 patients who obtained a CR had latency Type III, and the other with SD had latency Type II.
  • These results demonstrate that immunodeficiency caused by MTX treatment is associated with the development of EBV-related NHL in RA patients.
  • In patients who were treated by MTX for RA and developed NHL, remission can be observed following MTX withdrawal especially in NHL with latency Type III EBV infection.
  • The analysis of EBV infection, including the latency types, is useful to decide the optimum therapeutic strategy.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Epstein-Barr Virus Infections / complications. Lymphoma, Non-Hodgkin / chemically induced. Methotrexate / therapeutic use
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome


5. Marotta D, Sgambato A, Cerciello S, Magarelli N, Martini M, Larocca LM, Maccauro G: Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World J Surg Oncol; 2008;6:111
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.
  • BACKGROUND: The risk of developing lymphoma is greatly increased in HIV infection.
  • Musculoskeletal manifestations of the human immunodeficiency virus (HIV) are common and are sometimes the initial presentation of the disease.
  • HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.
  • The patient decided to continue her pregnancy and to not undergo any diagnostic procedure and treatment.
  • The lesion was also negative for EBV infection and showed a monoclonal rearrangement of IgH chain and a polyclonal pattern for TCR gamma and beta.
  • A final diagnosis of diffuse large B-cell lymphoma was made.
  • The patient underwent postoperative chemotherapy.
  • CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Pregnancy. Risk Assessment. Shoulder. Surgical Procedures, Operative / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]
  • [Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]
  • [Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]
  • [Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]
  • [Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]
  • [Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]
  • [Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]
  • [Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]
  • [Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]
  • (PMID = 18939988.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


6. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM: Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol; 2000 Oct;111(1):239-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies.
  • Cell-free Epstein-Barr virus (EBV) DNA has recently been detected in the plasma and serum of patients with Hodgkin's disease, post-transplant lymphoproliferative disease (PTLD) and acquired immunodeficiency syndrome-related lymphoma.
  • However, no data are available on the temporal variation of plasma/serum EBV DNA levels in patients with EBV-associated lymphoid malignancies during the course of therapy.
  • Using a real-time quantitative polymerase chain reaction assay, we studied the plasma EBV DNA levels in 13 patients with EBV-associated lymphoid malignancies (six patients with Hodgkin's disease, four with nasal natural killer/T-cell lymphoma, two cases of PTLD and one patient with Burkitt's lymphoma) at presentation and during therapy.
  • Plasma EBV DNA was detected in 12 of the 13 patients (median 2,266 copies/ml; interquartile range 181-8,379 copies/ml), but not in any of 35 healthy control subjects (P < 0.0001).
  • The EBV status in tumour cells was also examined in 12 of these patients using in situ hybridization for EBV-encoded small RNAs (EBERs).
  • EBER positivity was observed in 11 patients, all of whom had EBV DNA detectable in plasma.
  • The one patient who had no detectable plasma EBV DNA was also negative for EBERs in tumour tissue.
  • Serial measurements of plasma EBV DNA levels were performed in nine of the patients during the course of therapy.
  • All patients who responded to therapy demonstrated a significant reduction of plasma EBV DNA to low or undetectable levels, whereas in two patients with ineffective therapy, disease progression was associated with a rapid increase in plasma EBV DNA levels.
  • We concluded that plasma EBV DNA is detectable in a wide range of EBV-associated lymphoid malignancies.
  • As plasma EBV DNA levels correlate well with the therapeutic response, such analysis may be a valuable tool for monitoring clinical progress.
  • [MeSH-major] DNA, Viral / blood. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antiviral Agents / therapeutic use. Case-Control Studies. Disease Progression. Female. Follow-Up Studies. Humans. In Situ Hybridization. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / virology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / virology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / virology. Male. Middle Aged. Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11091207.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral
  •  go-up   go-down


7. Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Assis MG, Eiras DP, Dobo C, Oliveira JS: Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil. Hematol Oncol; 2010 Sep;28(3):137-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil.
  • INTRODUCTION: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein-Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells.
  • However, the impact of the presence of EBV in RS cells and its prognosis are still controversial.
  • We analysed the presence of EBV in RS cells and its influence in the clinical evolution of patients with cHL treated in two public hospitals in the city of São Paulo, Brazil.
  • Patients were only included in this study if they had (1) >18 years, (2) negative HIV serology, (3) undergone similar chemotherapy protocols, (4) paraffin blocks available with enough material for systematic review and histological reclassification and for detection of EBV in RS cells by in situ hybridization and immunohistochemistry and (5) clinical, epidemiological and laboratorial parameters available after a thorough chart review.
  • RESULTS: EBV was identified in 52.5% of the cases.
  • Mixed cellularity (MC) subtype was more common in EBV-related tumours (25.5%) (p=0.005).
  • The presence of EBV did not influence event free survival (EFS) (p=0.38) or overall survival (OS) (p=0.80) with a median follow-up of 80 months.
  • CONCLUSION: We demonstrate that the prevalence of EBV-related cHL in this Brazilian population is 52.5% and, that, the presence of EBV does not change the clinical evolution and OS of patients treated with similar chemotherapy protocols.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20128016.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Fätkenheuer G, Hell K, Roers A, Diehl V, Salzberger B: Spontaneous regression of HIV associated T-cell non-Hodgkin's lymphoma with highly active antiretroviral therapy. Eur J Med Res; 2000 Jun 20;5(6):236-40
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of HIV associated T-cell non-Hodgkin's lymphoma with highly active antiretroviral therapy.
  • A subcutaneous, T-phenotypic anaplastic large cell lymphoma (CD30/Ki1-positive, EBV positive) was diagnosed in a HIV-infected bisexual man.
  • Without chemotherapy the patient had a sustained long-term remission of this tumor (more than three years) after the initiation of highly active antiretroviral therapy.
  • Improvement of cellular immune function by antiretroviral therapy is the only recognizable factor which may have led to tumor remission.
  • This hypothesis is supported by parallels to EBV associated polyclonal lymphoproliferation in allogeneic transplantat recipients where regression of lymphoma can be induced by reducing immunosuppressive therapy.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Regression, Spontaneous
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10882638.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


9. Fong IW, Ho J, Toy C, Lo B, Fong MW: Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clin Infect Dis; 2000 May;30(5):757-61
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies.
  • Acyclovir or similar agents with activity against Epstein-Barr virus (EBV) theoretically may prevent non-Hodgkin's lymphoma (NHL) in AIDS.
  • A case-control study of 29 patients with AIDS-related NHL and 58 matched control subjects assessed the frequency with which daily acyclovir (>/=800 mg/d) or similar agents were used for > or =1 year.
  • In a historical cohort of 304 patients with AIDS for > or =2 years, the prevalence of NHL was assessed among 3 groups of patients: those who received long-term treatment with high-dose acyclovir (or similar agents) or low-dose or intermittent acyclovir; those treated with ganciclovir/foscarnet for <1 year; and those who had not previously been treated with acyclovir, ganciclovir, or foscarnet.
  • In the case-control study, 22 patients (72.4%) with NHL never received acyclovir or similar drugs versus 19 control subjects (32.8%; P=.
  • In the cohort study, 6 (6.8%) of 88 patients who received acyclovir (> or =800 mg/d) for > or =1 year developed NHL versus 15 (15.5%) of 97 patients who received intermittent or lower-dose acyclovir and 30 (25.2%) of 119 patients who never received these agents (P=.002).
  • Long-term administration (>1 year) of high-dose acyclovir or similar agents with anti-EBV activity may prevent NHL in patients with AIDS.
  • [MeSH-major] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Lymphoma, AIDS-Related / prevention & control
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Drug Therapy, Combination. Epstein-Barr Virus Infections / drug therapy. Female. Foscarnet / therapeutic use. Ganciclovir / therapeutic use. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Foscarnet .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2001 Mar 15;32(6):989-90 [11247725.001]
  • [CommentIn] Clin Infect Dis. 2000 May;30(5):762-3 [10816145.001]
  • (PMID = 10816144.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 364P9RVW4X / Foscarnet; P9G3CKZ4P5 / Ganciclovir; X4HES1O11F / Acyclovir
  •  go-up   go-down


10. Seinturier C, Péoch M, Morand P, Jacob MC, Gressin R, Brion JP: [Malignant non-Hodgkins B lymphoma related to Epstein-Barr virus and chronic natural killer lymphocytosis in a immunocompromised patient]. Rev Med Interne; 2000 Mar;21(3):290-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkins B lymphoma related to Epstein-Barr virus and chronic natural killer lymphocytosis in a immunocompromised patient].
  • [Transliterated title] Lymphome malin non Hodgkinien B associé au virus d'Epstein-Barr et lymphocytose chronique à cellules natural killer chez une patiente immunodéprimée.
  • INTRODUCTION: Immunocompromised patients are at high risk of Epstein-Barr virus (EBV)-related lymphoproliferative disorders.
  • She developed an opportunistic pneumonia while immunodepressed during long-term corticotherapy aimed at curing her auto-immune disease.
  • Chronic lymphocytosis was also diagnosed at this time.
  • Several months later, non-Hodgkin's lymphoma was diagnosed.
  • Genomic amplification of the Epstein-Barr virus in the patient's blood and positive EBV latent membrane protein 1 on the lymph nodes provided evidence for a strong correlation between EBV reactivation and lymphoma.
  • CONCLUSION: Two distinct lymphoid diseases occurred during the immunosuppressive therapy for the auto-immune disease.
  • PCR monitoring of Epstein-Barr virus allows for early screening of lymphoproliferative disorders in immunocompromised patients, leading to earlier and more efficient treatment.

  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10763192.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Steroids
  •  go-up   go-down


11. Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K: Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol; 2002 Oct 15;20(20):4255-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyothorax-associated lymphoma: a review of 106 cases.
  • PURPOSE: Pyothorax-associated lymphoma (PAL) is a non-Hodgkin's lymphoma developing in the pleural cavity after a long-standing history of pyothorax.
  • All patients had a 20- to 64-year (median, 37-year) history of pyothorax resulting from artificial pneumothorax for treatment of pulmonary tuberculosis (80%) or tuberculous pleuritis (17%).
  • Histologically, PAL usually showed a diffuse proliferation of large cells of B-cell type (88%).
  • In situ hybridization study showed that PAL in 70% of the patients was Epstein-Barr virus (EBV)-positive.
  • PAL was responsive to chemotherapy, but the overall prognosis was poor, with a 5-year survival of 21.6%.
  • PAL is a non-Hodgkin's lymphoma of exclusively B-cell phenotype in the pleural cavity of patients with long-standing history of pyothorax, and is strongly associated with EBV infection.
  • Development of PAL is closely related to antecedent chronic inflammatory condition; therefore, PAL should be defined as malignant lymphoma developing in chronic inflammation.
  • [MeSH-major] Empyema, Pleural / complications. Lymphoma, Non-Hodgkin / etiology. Pleural Neoplasms / etiology
  • [MeSH-minor] Aged. Aged, 80 and over. Chronic Disease. Epstein-Barr Virus Infections / complications. Female. Humans. Male. Middle Aged. Pneumothorax, Artificial / adverse effects. Survival Analysis. Tuberculosis, Pleural / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377970.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Porcu P, Caligiuri MA: Acquired immunodeficiency syndrome-related lymphomas: future directions. Semin Oncol; 2000 Aug;27(4):454-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome-related lymphomas: future directions.
  • Despite some exciting new leads, human immunodeficiency virus-I (HIV-I)-related non-Hodgkin's lymphoma (HIV-NHL) remains a fatal malignancy for the vast majority of patients.
  • The use of highly active antiretroviral therapy (HAART) has not produced a fall in the incidence of HIV-NHL and conventional cytotoxic chemotherapy is associated with a negligible cure rate.
  • New treatment options are needed.
  • Future therapeutic directions in HIV-NHL should be based on a better understanding of three fundamental aspects of lymphomagenesis in the setting of acquired immunodeficiency. (I) New information on the molecular and pathological heterogeneity of HIV-NHL should be applied to the development of risk-adapted therapy.
  • The identification of patient subsets with different susceptibility to cytotoxic chemotherapy, immunomodulation, or antiviral strategies is essential for the design of clinical trials of investigational new agents in HIV-NHL. (2) Known viral pathogens need to be better understood.
  • Key biological interactions between virus and host, mediated by oncogenic, immunomodulatory, and antiapoptotic viral proteins, should become the main target for new drug development. (3) Immune reconstitution with HAART and immunostimulatory cytokines such as interleukin-2 (IL-2) and IL-12, combined with drugs that downregulate the replication or gene expression of tumor-associated viruses such as Epstein-Barr virus (EBV) and human herpes virus-8 (HHV-8), possibly in combination, should remain a primary goal in the treatment of HIV-NHL.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. HIV / physiology. Herpesvirus 4, Human. Humans


13. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X: Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):e19546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL).
  • : e19546 Background: Rituximab (R) is increasingly used for the treatment of B-NHL.
  • METHODS: The records of consecutive pts treated at 2 institutions from 01/06 to 12/08 with R-containing chemotherapy or R-maintenance therapy (R-M) for NHL were analyzed for severe UT and OI.
  • UT was considered as related to R if it could not be explained otherwise.
  • UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia.
  • IP completely resolved after initiation of prednisone (n=1) or under empiric antimicrobial therapy (n=1).
  • Congestive heart failure improved under appropriate therapy and the pt received 2 more cycles of R-M.
  • Pancytopenia slowly recovered under therapy with G-CSF, R was terminated.
  • OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma.
  • Infections resolved under antimicrobial therapy.
  • EBV-hepatitis improved spontaneously.
  • Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1).
  • Awareness of UT/OI, rapid diagnostic proceedings and, whenever possible, initiation of therapy are essential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Alarcon-Rozas AE, Cardenas RA, Villacres K, Salas F, Guevara J, Hernandez E: Study of prevalence of seropositivity from seven different virus associated to non Hodgkin's lymphoma (NHL). J Clin Oncol; 2004 Jul 15;22(14_suppl):6689

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of prevalence of seropositivity from seven different virus associated to non Hodgkin's lymphoma (NHL).
  • - NHL is the 5th leading cause of cancer mortality in Peru and it is well known that some virus are associated to NHL like EBV for Burkitt and posttransplantation lymphoma as well as HTLV-I for ATLL.
  • There are emerging virus related to NHL like HCV, CMV, HIV, and HSV.
  • PATIENTS AND METHODS: - We collect 60 new patients with confirmed NHL by pathology at Guillermo Almenara Hospital and HMC from 6/99 to 6/02, we took a blood sample for analizing the seropositivity measuring the level of IgG and IgM for HSV-I, HSV-II, EBV and CMV or by ELISA for HCV, HTLV-I and HIV.
  • We do not accept NHL patients already in chemotherapy because many of them could have been infected by some of these virus during the neutropenic period.
  • - Seropositivity by virus Tabla II.
  • Finally the memory of B cells of viral infections, expressed in high levels of IgG is important for EBV and HSV-I (75% and 78% respectevely); and for acute infection EBV 10% and CMV 7%.
  • We need a case-control study to determine the significance of these results as well as molecular analisis in order to know if the insertion of viral genome is really in the lymphoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Colombi M, Guffanti A, Alietti A, Latargia ML, Vener C, Maiolo AT, Baldini L: OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma. Leuk Lymphoma; 2000 Dec;40(1-2):87-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
  • With the aim of developing an effective therapy for heavily pretreated refractory MM outpatients, we evaluated the OPPEBVCAD regimen, a Hodgkin's disease-derived protocol that includes many drugs effective in MM administered in a sequential schedule.
  • Twenty-two pts aged 42-72 years, with symptomatic highly-pretreated refractory (18 cases), or primary resistant MM (four cases. including two pts with plasma cell leukemia-PCL) received this therapy every 28 days (2-4 cycles, followed by a maintenance program).
  • Therapeutic response (Chronic Leukemia-Myeloma Task Force criteria) and performance status (PS) and pain (W.H.O.) were evaluated.
  • The most frequent side effects were cytopenias, with one drug related infective death.
  • The OPPEBVCAD regimen proved to be an effective therapy for refractory relapsing or primary resistant MM: in responders (two-thirds of the pts), survival was prolonged by about 10 months.
  • Its efficacy in anthracycline-treated pts, as well as the feasibility of using it on an outpatient basis without any continuous drug infusions, make this regimen a promising third line salvage therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epirubicin / administration & dosage. Multiple Myeloma / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage. Vindesine / administration & dosage
  • [MeSH-minor] Adult. Aged. Agranulocytosis / chemically induced. Anemia / chemically induced. Bleomycin / administration & dosage. Bleomycin / toxicity. Cause of Death. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Lomustine / administration & dosage. Lomustine / toxicity. Melphalan / administration & dosage. Melphalan / toxicity. Middle Aged. Procarbazine / administration & dosage. Procarbazine / toxicity. Salvage Therapy / methods. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / toxicity

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426632.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; Q41OR9510P / Melphalan; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CAD protocol 1; EBV protocol; OPP protocol; OPP-EBV-CAD regimen
  •  go-up   go-down


16. Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM: Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma; 2002 Feb;43(2):423-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.
  • We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region.
  • Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) producing sheets of cells with an organoid distribution.
  • These studies were supportive of a diagnosis of a plasmablastic lymphoma.
  • Treatment with CHOP chemotherapy with filgrastim support was begun which resulted in another remission.
  • Plasmablastic lymphoma is now reported in some studies to account for 2.6% of all HIV-related NHL.
  • Co-infection with HHV-8 and EBV has not been consistently reported.
  • Therapy with standard regimens has variable response.
  • The regression of disease after resumption of HAART therapy alone in this patient suggests that HAART has an important role in the treatment of lymphoma in the HIV infected patient.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. HIV Infections / complications. HIV Infections / drug therapy. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Remission Induction

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999580.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


17. Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW: [Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease]. Ned Tijdschr Geneeskd; 2005 Aug 13;149(33):1859-63
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease].
  • [Transliterated title] Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte.
  • During treatment for inflammatory bowel disease (IBD) 2 men with ulcerative colitis, aged 52 and 38 years, and a 37-year-old man with Crohn's disease developed Epstein-Barr virus (EBV)-related non-Hodgkin's B-cell lymphoma.
  • The first 2 patients underwent proctocolectomy and the use of immunosuppressive agents was discontinued, after which the lymphoma disappeared.
  • Azathioprine and 6-mercaptopurine are first choice therapy in the treatment of steroid-refractory IBD.
  • These immunomodulating agents are associated with the development of EBV-positive lymphomas in the setting of solid organ transplantation.
  • This type of lymphoma is a rare complication in IBD, although the incidence in referral centres appears to be increasing.
  • Since azathioprine is an important drug in IBD, there is a need for identification of IBD patients at risk of developing a lymphoma.
  • EBV-DNA in plasma or in faeces may be a candidate tumour marker.
  • [MeSH-major] Colitis, Ulcerative / complications. Crohn Disease / complications. Epstein-Barr Virus Infections / complications. Lymphoma, B-Cell / virology
  • [MeSH-minor] 6-Mercaptopurine / adverse effects. 6-Mercaptopurine / therapeutic use. Adult. Azathioprine / adverse effects. Azathioprine / therapeutic use. Fatal Outcome. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128185.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine; MRK240IY2L / Azathioprine
  •  go-up   go-down


18. Unholzer A, Starz H, Hirschsteiner O, Balda BR: [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient]. J Dtsch Dermatol Ges; 2005 Jan;3(1):46-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
  • Compared to the general population, the organ transplant patients have a 30-60 fold increased risk of developing non-Hodgkin's lymphoma.
  • A 55-year-old, hepatitis C-positive man developed an Epstein-Barr virus (EBV)- negative Burkitt lymphoma (BL) first appearing on the gingiva under immunosuppressive therapy nine years after allogenic renal transplantation.
  • In 70% of BL occurring after organ transplantation, genes or gene products related to EBV can be demonstrated within the tumor cells.
  • The EBV status of the tumor is of important prognostic significance: EBV-positive BL occurring in organ transplant patients usually responds well to reduction or cessation of immunosuppressive therapy; in some cases permanent complete remissions can be achieved even without chemotherapy.
  • In contrast, patients with EBV-negative BL have a very poor prognosis and hardly respond, even to aggressive chemotherapy protocols.
  • [MeSH-major] Burkitt Lymphoma / etiology. Gingival Neoplasms / etiology. Hepatitis C / complications. Immunocompromised Host. Kidney Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gingiva / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353750.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • Therapy strategies including chemotherapy, immunotherapy and HAART will show promising results in response and survival rates.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Endoscopy, Gastrointestinal. Humans. Immunotherapy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


20. Comito MA, Sun Q, Lucas KG: Immunotherapy for Epstein-Barr virus-associated tumors. Leuk Lymphoma; 2004 Oct;45(10):1981-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for Epstein-Barr virus-associated tumors.
  • Epstein-Barr Virus (EBV) is associated with a number of tumors, including lymphomas in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, patients with the acquired immunodeficiency syndrome (AIDS), Burkitt's lymphoma, as well as a subset of patients with nasopharyngeal carcinoma (NPC) and Hodgkin's disease (HD).
  • The types of latent EBV infections vary in these tumors, which influences the EBV antigens expressed and ultimately the immunogenicity of tumor cells.
  • Not all EBV associated malignancies are directly related to altered cellular immunity, as is the case with EBV induced lymphoproliferations in immunocompromised patients.
  • Treatment strategies have ranged from restoration of normal cellular immunity, which is generally successful in SOT and HSCT patients, anti-B cell monoclonal antibodies, and conventional chemotherapy and radiation.
  • The fact that these tumors express EBV antigens for which many individuals have high circulating levels of protective cytotoxic T lymphocytes (CTL) has lead to investigation into the applicability of adoptive transfer of EBV specific T cells.
  • Initial success with adoptive immunotherapy for HSCT and SOT patients has lead to current studies examining the feasibility and efficacy of this strategy for other EBV associated tumors, such as NPC and HD.
  • We will review the pathogenesis of these disorders, current therapies, and future investigations aimed at targeting EBV antigen expression on these tumors.
  • [MeSH-major] Herpesvirus 4, Human / immunology. Immunotherapy, Adoptive / methods. Lymphoma / therapy
  • [MeSH-minor] Antigens, Viral / immunology. Antigens, Viral / therapeutic use. Humans. Neoplasms / therapy. Neoplasms / virology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370241.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral
  • [Number-of-references] 77
  •  go-up   go-down


21. Snanoudj R, Durrbach A, Leblond V, Caillard S, Hurault De Ligny B, Noel C, Rondeau E, Moulin B, Mamzer-Bruneel MF, Lacroix C, Charpentier B: Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation; 2003 Sep 27;76(6):930-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma is the second most frequent neoplasia following solid-organ transplantation.
  • Median overall delay between transplantation and lymphoma was 18 months (4-264).
  • Six of 10 patients with late posttransplantation brain lymphomas (PTBL) occurrence (>3 years) had been recently switched from azathioprine to mycophenolate mofetil (median switch lymphoma delay 14 months).
  • Cerebral computed tomography (CT) scans and magnetic resonance imaging (MRI) revealed multifocal lesions (n=18), with a ring contrast enhancement (n=20) similar to cerebral abscesses, as observed in HIV-related brain lymphomas.
  • Histology showed large B-cell non-Hodgkin's lymphoma in 87.5% of cases; Epstein-Barr virus (EBV) was detected in 95%.
  • After lymphoma diagnosis, immunosuppressive treatment was reduced in all patients, and all but one received complementary treatment by surgery (n=2), anti-CD21 antibodies (n=2), chemotherapy including high-dose intravenous methotrexate (n=7), encephalic radiotherapy (n=5), or chemotherapy plus radiotherapy (n=8).
  • CONCLUSIONS: Our study showed that PTBL are EBV-induced large B-cell lymphomas, which mimic cerebral abscesses on imaging and whose occurrence may be influenced by immunosuppression modifications.
  • Treatment by radiotherapy is associated with better survival.
  • [MeSH-major] Brain Neoplasms / epidemiology. Kidney Transplantation / adverse effects. Lymphoma / epidemiology
  • [MeSH-minor] Adult. Antilymphocyte Serum / therapeutic use. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Intracranial Hypertension / epidemiology. Male. Middle Aged. Nervous System Diseases / epidemiology. Postoperative Complications. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14508356.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP: Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation; 2004 Feb 15;77(3):431-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median time from transplantation to the onset of LPD was 5.8 years.
  • The time to diagnosis of LPD was significantly shorter for Epstein-Barr virus (EBV)-seronegative than for EBV-seropositive recipients (median, 175 vs. 2255 days; log-rank, P<0.001).
  • Seventeen cases were non-Hodgkin's lymphomas, one was a Burkitt's lymphoma, and one was an atypical lymphoid proliferation.
  • Immunosuppressive therapy was decreased in all patients.
  • Eleven underwent surgical resection, and nine received chemotherapy.
  • The median time from the diagnosis of LPD to death was 68 days.
  • CONCLUSIONS: Abdominal-pelvic LPD is typically a late complication after lung transplantation; however, when it occurs early, it may be related to a primary EBV infection.
  • This form of LPD is most frequently a non-Hodgkin's lymphoma, and despite aggressive therapy, the prognosis is poor.
  • [MeSH-minor] Burkitt Lymphoma / etiology. Dose-Response Relationship, Drug. Epstein-Barr Virus Infections / complications. Female. Gastrointestinal Diseases / etiology. Humans. Immunosuppressive Agents / administration & dosage. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14966421.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


23. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ: Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr; 2005 May;40(5):582-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective review of presenting features, treatment and long-term outcome in a series of 8 children with typical IE.
  • Three children developed a generalised lymphadenopathy due to uncontrolled EBV-related lymphoid proliferations (ages 4, 12, 18).
  • These comprised a monomorphous B-lymphoycte lympho-proliferative disorder, a large pleomorphic follicular lymphoma, and a high grade pleomorphic B cell non-Hodgkin's lymphoma.
  • CONCLUSIONS: Infants with IE have a high risk of developing lymphomatous proliferations that appears to be related to the underlying immunodysregulation.
  • Use of aggressive immunosuppression and acquisition of EBV infection appears to accelerate this process; hence we advocate early colectomy in confirmed cases.
  • In children with IE screening for EBV and vigilance for abnormal lymphoid proliferations is paramount.
  • [MeSH-major] Colectomy. Colitis, Ulcerative / drug therapy. Colitis, Ulcerative / surgery. Enterocolitis / drug therapy. Enterocolitis / surgery. Immunosuppressive Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Azathioprine / therapeutic use. Child. Child, Preschool. Chronic Disease. Cyclosporine / therapeutic use. Epstein-Barr Virus Infections / epidemiology. Female. Follow-Up Studies. Humans. Immunoglobulins / therapeutic use. Infant. Infant, Newborn. Lymphoma, Non-Hodgkin / epidemiology. Lymphoproliferative Disorders / epidemiology. Male. Steroids / therapeutic use. Thalidomide / therapeutic use. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861020.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Immunosuppressive Agents; 0 / Steroids; 4Z8R6ORS6L / Thalidomide; 83HN0GTJ6D / Cyclosporine; MRK240IY2L / Azathioprine
  •  go-up   go-down


24. Vila L, Moreno L, Andrés MM, Fernández JM, Verdeguer A, Pérez-Valle S, Sangüesa C, Berbel O, Castel V: Could other viruses cause pediatric posttransplant lymphoproliferative disorder? Clin Transl Oncol; 2008 Jul;10(7):422-5
MedlinePlus Health Information. consumer health - Viral Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We summarize the experience of our hospital, one of Spain's largest series of renal (294), liver (47) and allogeneic stem cell transplants (67), where four cases of PTLD have developed related to complex viral infections.
  • He was seropositive for Epstein-Barr virus (EBV) and developed an aggressive Bcell non-Hodgkin's lymphoma (B-NHL) related to EBV reactivation and human herpesvirus 6 (HHV-6) infection.
  • Cases 2, 3, and 4 developed after kidney transplantation and were all EBV seronegative.
  • Case 2 had associated cytomegalovirus (CMV) and EBV infection.
  • Cases 3 and 4 only revealed EBV viral load.
  • Although EBV plays a clear role in its pathogenesis, other associated viral infections could trigger this situation.
  • Current therapies include rituximab, decreasing immunosuppressive drugs. and conventional chemotherapy.
  • [MeSH-major] Lymphoproliferative Disorders / virology. Postoperative Complications / virology. Tumor Virus Infections / virology. Virus Diseases / complications
  • [MeSH-minor] Child. Child, Preschool. Cytomegalovirus. Cytomegalovirus Infections / complications. Cytomegalovirus Infections / epidemiology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human. Humans. Infant. Infant, Newborn. Kidney Transplantation / adverse effects. Male. Stem Cell Transplantation / adverse effects. Viral Load

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2001 Aug;5(4):250-7 [11472603.001]
  • [Cites] Herpes. 2003 Dec;10(3):60-5 [14759337.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Blood. 2001 Aug 15;98(4):972-8 [11493441.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1462-7 [9395355.001]
  • [Cites] Transplantation. 1999 Dec 27;68(12):1851-4 [10628763.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):70-8 [11395972.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • [Cites] Transplantation. 2002 Jan 15;73(1):100-4 [11792987.001]
  • (PMID = 18628071.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Mismatched double-stranded RNA: polyI:polyC12U. Drugs R D; 2004;5(5):297-304
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ampligen, currently under development by Hemispherx Biopharma in the US, acts on the immunological system through T-lymphocyte stimulation and is indicated for the treatment of chronic fatigue syndrome and acquired immunodeficiency deficiency syndrome (AIDS), as part of the combined therapy.
  • In February 2004, Fujisawa Deutschland GmbH, a subsidiary of Fujisawa Pharmaceutical Co., entered into an option agreement with Hemispherx Biopharma with the intent of becoming a distributor for Ampligen for the potential treatment of chronic fatigue syndrome in Germany, Switzerland and Austria.
  • The agreement stipulates that the Guangdong Medicine Group Corporation (GMC) will conduct clinical trials with Ampligen for the treatment of HIV.
  • All costs related to the trials are to be covered by GMC.
  • In May 2003, Hemispherx Biopharma and the Center for Cell and Gene Therapy entered into a research project agreement that will see Ampligen implemented in a protocol used in patients with relapsed EBV-positive Hodgkin's Lymphoma.
  • In March 2002, Esteve and Hemispherx Biopharma entered into a collaborative agreement under which Esteve will be the sole distributor of Ampligen in Spain, Portugal and Andorra for the treatment of chronic fatigue syndrome.
  • Under this agreement, in addition to other terms, Esteve will also collaborate in the drug product development by conducting clinical studies in Spain in patients coinfected with HIV/HCV.
  • In July 2001 Hemispherx Biopharma announced that it had formed a strategic alliance with Empire Health Resources for clinical trials of Ampligen in the treatment of HIV and hepatitis C virus infections.
  • Hemispherx and AOP Orphan Pharmaceuticals have signed a marketing agreement for Ampligen for the treatment of chronic fatigue syndrome for Austria, the Czech Republic, Poland and Hungary.
  • In the US, Ampligen has been granted orphan drug status for the treatment of AIDS, renal cell carcinoma (phase II, completed), chronic fatigue syndrome (phase III) and invasive/metastatic malignant melanoma (phase II).
  • Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen for the treatment of chronic fatigue syndrome; the first stage of th;) for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared.
  • In 2000, Hemispherx Europe (Hemispherx) obtained orphan drug status for Ampligen for the treatment of chronic fatigue syndrome in the EU, providing Hemispherx with 10 years of marketing exclusivity following the launch of the drug, as well as potential financial research benefits for the agent.
  • In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome.
  • In the meantime, Ampligen has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma).
  • Bioclones has initiated clinical studies with Ampligen for the treatment of chronic fatigue syndrome in Australia.
  • Clinical treatment programmes for chronic fatigue syndrome in other Pacific Rim countries are planned.
  • Hemispherx has developed a 'ready-to-use' liquid formulation of the drug and has begun treating patients with chronic fatigue syndrome in ongoing clinical trials.
  • Hemispherx has also developed an oral version of the drug (Oragen), which is undergoing preclinical evaluation.
  • In February 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union.
  • Patients treated in these studies will have exhausted all other treatment options.
  • The trial, comprising two studies, REARMI and REARMII (Research/Evaluation of Ampligen for Retroviral Mutations I and II), will evaluate the ability of Ampligen to prevent the emergence of mutated, drug-resistant strains of the virus.
  • 'Several hundred' patients currently on antiretroviral therapy and at risk of viral relapse will be enrolled at centres in Connecticut, New York, Florida and California.
  • A second phase IIb study evaluating the effect of Ampligen on structured treatment interruptions (STI) is also underway.
  • NIH sponsored studies of potential therapies for SARS have identified Ampligen as having unusually high and consistent antiviral activity against human coronavirus, the pathogen implicated as the causative agent of the disease.
  • Independent researchers have demonstrated the antiviral activity of Ampligen against flaviviruses (West Nile virus, Equine Encephalitis virus, Dengue fever virus and Japanese Encephalitis virus) as well as virus classes associated with bioterrorism.
  • In an animal study, Ampligen was shown to prevent destruction of nerve cells, reduce virus concentrations in the brain and blood stream and increase survival rates.
  • Researchers at the Rega Institute in Belgium have published results from an animal study demonstrating that Ampligen was superior at protecting mice against coxsackie B3 virus-induced myocarditis compared with pegylated interferon.
  • In May 2004 Hemispherx announced that it had filed an expanded US patent application covering the use of Ampligen for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Poly I-C / therapeutic use. Poly U / therapeutic use. RNA, Double-Stranded / therapeutic use. Virus Diseases / drug therapy
  • [MeSH-minor] Animals. Anti-HIV Agents / pharmacology. Anti-HIV Agents / therapeutic use. Base Pair Mismatch. Drug Interactions. Hepatitis B / drug therapy. Humans. Mice. Nervous System Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Adis Data Information BV
  • (PMID = 15357629.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / RNA, Double-Stranded; 0 / poly(I).poly(c12,U); 24939-03-5 / Poly I-C; 27416-86-0 / Poly U
  •  go-up   go-down






Advertisement